Related content

Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1327-1332

Spandidos Publications

Access to resources Recommend Favorite

A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer

By Mok Tony   Leung Thomas   Brown Gill   Moyses Chris   Chan Anthony   Yeo Winnie   Wong Herman   Chak Karen   Johnson Philip  

Acta Oncologica, Vol. 43, Iss. 3, 2004-04 ,pp. : 245-251

Informa Healthcare

Access to resources Recommend Favorite

Bendamustine as a model for the activity of alkylating agents

By Apostolopoulos Christos   Castellano Leandro   Stebbing Justin   Giamas Georgios  

Future Oncology, Vol. 4, Iss. 3, 2008-06 ,pp. : 323-332

Future Medicine

Access to resources Recommend Favorite

Bendamustine pharmacokinetic profile and exposure–response relationships in patients with indolent non-Hodgkin’s lymphoma

By Owen Joel   Melhem Murad   Passarell Julie   D’Andrea Denise   Darwish Mona   Kahl Bradley  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1039-1049

Springer Publishing Company

Access to resources Recommend Favorite

The safety of bendamustine in patients with chronic lymphocytic leukemia or non-Hodgkin lymphoma and concomitant renal impairment: a retrospective electronic medical record database analysis

By Nordstrom Beth L.   Knopf Kevin B.   Teltsch Dana Y.   Engle Robert   Beygi Hooman   Sterchele James A.  

Leukemia and Lymphoma, Vol. 55, Iss. 6, 2014-06 ,pp. : 1266-1273

Informa Healthcare

Access to resources Recommend Favorite